

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Julie Hazel Campbell et al.

Serial No.:

10/628,308

Filing Date:

July 29, 2003

For:

IMPLANT MATERIAL

Examiner: Urmi CHATTOPADHYAY

Group Art Unit: 1651

INFORMATION DISCLOSURE STATEMENT

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/763,359, filed February 21, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of recording the application.

This Information Disclosure Statement is submitted before mailing of a first Office Action on the merits; accordingly, no fee or other requirement is required.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 CFR 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application

does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the event that the transmittal letter is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 229752001220

Dated: April 22, 2004

Respectfully submitted,

Jonathan Bockman Registration No. 45,640

Morrison & Foerster LLP 1650 Tysons Boulevard Suite 300

McLean, VA 22102-3915 Telephone: (703)760-7769

Form PTO-1449 Docket Number 229752001220 Application Number 10/628,308 INFORMATION DISCLOSURE CITATION Applicant Julie Hazel Campbell IN AN APPLICATION PE (Use several sheets if necessary Filing Date July 29, 2003 Group Art Unit1651 Mailing Date: April 22, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12-7-1971	3,625,198	Charles H. Sparks			5-9-1969
	2.	12-25-1984	4,490,137	Moukheibir			9-30-1982
	3.	8-29-2000	6,110,188	Narcisco, Jr.			3-9-1998
	4.	9-12-2000	6,117,166	Winston			10-27-1997
	5.	9-30-2003	6,626,823	Campbell et al.			8-20-1999

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country.	Class	Subclass	Translation YES NO	
	6.	10/24/1990	0.393 788 A2	EPO			X	
	7.	02/12/1992	0.470.681.A2	EPO			Х	
	8.	05/18/1994	0.597 810 A2	EPO.			X	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

9.	Campbell et al. "Cytodifferentiation and Expression of α-Smooth Muscle Actin mRNA and Protein during Primary Culture of Aortic Smooth Muscle Cells" Arteriosclerosis 9(5): 633-643, 1989.
10.	Desmouliere et al. "Role of the myofibroblast differentiation during liver fibrosis" Journal of Hepatology 22:61-64, 1995.
11.	Edwards et al. "Development of an Ovine Collagen-based Composite Biosynthetic Vascular Prosthesis" Clinical Material 9:211-223, 1992.
12.	Härtig et al. "Blot analyses and immunocytochemistry of neural antigens with digoxigenylated primary and secondary antibodies" Brain Research Protocols 2(1)35-43, 1997.
13.	Kleinert et al. "The neointima formed in endothelial cell sodded ePTFE vascular grafts results from both cellular-hyperplasia and extracellular-hypertrophy" Cell Transplantation 5(4): 475-482, 1996.
14.	Koch et al. "Analysis of 274 omniflow vascular prostheses implanted over an eight-year period" Aust. N.Z. J. of Surg. 67:637-639, 1997.
1 1	10. 2.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<u> </u>			Sheet 2 of 2	
Form PTO-1449		Docket Number 229752001220	Application Number 10/628,308	
	TON DISCLOSURE CITATION N AN APPLICATION	Applicant Julie Hazel Campbell		
α	Use several sheets if necessary)	Filing Date July 29, 2003	Group Art Unit1651	
		Mailing Date : April 22, 2004		
116	1 1 1000			
15.	Kuo et al. "The potential of In Vivo vascular tissue engineering for the treatment of vascular			
	thrombosis: a preliminary report" An	n. J. Roentgenol. 171:553-558,	1998.	
16.	Manderson et al.: Venous response t	endothelial denudation" Journal of Pathology 18:77-87, 1986.		
17.	Puchkov et al. "Vascularization of humunosupressed by cyclosporine A	uman embryo neocortex in the	rat eve anterior chamber	
18.	Sappino et al. "Differentiation Reper Marker of Phenotypic Modulations"	toire of Fibroblastic Cells: Exp Lab. Investigation 63:144-161	pression of Cytoskeletal Proteins as , 1990.	
19.	Schwartz et al. "Subspecialty Clinics new perspectives from a porcine mod	3: Cardiology - Coronary restendel" <i>Mayo Clin. Proc.</i> 68:54-62	nosis: prospects for solution and 2, 1993.	
20.	Verhagen et al. "Thrombomodulin ac an alternative for endothelial cells for 95:542-549, 1996.	ctivity on mesothelial cells: per r cell seeding on vascular graft	rspectives for mesothelial cells as some British Journal of Haematology	
21.	Walden et al. "Matched elastic prope 1169, 1980.	erties and successful arterial gra	afting" Arch-Surg. 115(10):1166-	

EX	A۱	ΛT	٧Ē	R	•

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.